OncoGynecology Xagena
The aim of American Society of Clinical Oncology ( ASCO ) Clinical Practice Guideline is to provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients ...
Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. TH3RESA trial has compared Trastuzumab E ...
Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, Trastuzumab, and a Platinum s ...
Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. A stud ...
Results from the phase III clinical trial of the investigational drug PB272 ( Neratinib ) for the extended adjuvant treatment of breast cancer ( ExteNET Trial ). The ExteNET trial is a double-blind, ...
A new breast cancer vaccine candidate, ( GP2 ), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it ...
LABC ( Locally advanced breast cancer ) occurs at first presentation in about one-fifth of breast cancer patients worldwide, with lower incidence in countries with established screening programmes but ...
Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy ( Trastuzumab [ Herceptin ] and Lapatinib [ Tykerb ] ) ...
PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational status with pCR in patients with HER2-positive early breast cancer treated with ne ...
The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin ) plus chemotherapy increases the pathologic complete remission ( pCR ) rate comp ...
The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate ( ADC ) was evaluated in patients with HER2-positive, un ...
